Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia

Clinical Cancer Research

Volumn 19, Issue 24, 2013, Pages 6873-6881

  Kreitman, Robert J ^a   Wilson, Wyndham ^a   Calvo, Katherine R ^b   Arons, Evgeny ^a   Roth, Laura ^a   Sapolsky, Jeffrey ^a   Zhou, Hong ^a   Raffeld, Mark ^a   Stetler Stevenson, Maryalice ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CLADRIBINE; DIPHENHYDRAMINE; METHYLPREDNISOLONE; PARACETAMOL; PETHIDINE; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BONE MARROW; BONE PAIN; BRONCHOSPASM; CANCER STAGING; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLOW CYTOMETRY; FLU LIKE SYNDROME; FOLLOW UP; HAIRY CELL LEUKEMIA; HEADACHE; HEMATURIA; HUMAN; HUMAN TISSUE; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNOHISTOCHEMISTRY; INFUSION RELATED REACTION; LEUKEMIA REMISSION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RHINITIS; SORE THROAT; SYSTOLIC HYPERTENSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; VARIANT HAIRY CELL LEUKEMIA; VERY ELDERLY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84890753551     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1752     Document Type: Article

References (47)

1. Cawley JC, Burns GF, Hayhoe FG. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res 1980;4:547-59. (Pubitemid 11207672)
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4 ed, Vol. 2. World Health Organization; 2008.
3. Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995;13:974-82.
4. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92: 1918-26. (Pubitemid 28446680)
5. Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733-40.
6. Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 2001;15:184-6. (Pubitemid 32124084)
7. Robak T, Blasinska-Morawiec M, Blonski J, Hellmann A, Halaburda K, Konopka L, et al. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 1999;62:49-56. (Pubitemid 29029918)
8. Tetreault SA, Robbins BA, Saven A. Treatment of hairy cell leukemia-variant with cladribine. Leuk Lymphoma 1999;35:347-54.
9. Machii T, Chou T, Suzuki M, Ohe Y, Katagiri S, Kitano EK, et al. Phase II clinical study of cladribine in the treatment of hairy cell leukemia. Int J Hematol 2005;82:230-5. (Pubitemid 41552329)
10. Palomera L, Domingo JM, Sola C, Azaceta G, Calvo MT, Gutierrez M. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases. Haematologica 2002;87: 107-8. (Pubitemid 34101120)
11. + hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009;114:4687-95.
12. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012;366: 2038-40.
13. Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 2012;119:3330-2.
14. Tiacci E, Schiavoni G, Forconi F, Santi A, Trentin L, Ambrosetti A, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 2012;119:192-5.
15. Ravandi F, Jorgensen JL, O'Brien S M, Verstovsek S, Koller CA, Faderl S, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006;107:4658-62. (Pubitemid 43882611)
16. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 2011;118:3818-23.
17. Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002;87: 33-43. (Pubitemid 34101111)
18. Venkataraman G, Aguhar C, Kreitman RJ, Yuan CM, Stetler-Stevenson M. Characteristic CD103 and CD123 Expression Pattern Defines Hairy Cell Leukemia: Usefulness of CD123 and CD103 in the Diagnosis of Mature B-Cell Lymphoproliferative Disorders. Am J Clin Pathol 2011;136:625-30.
19. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, FitzGerald DJP, Wilson WH, et al. Phase II trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009;27:2983-90.
20. Tallman MS, Hakimian D, Kopecky KJ, Wheaton S, Wollins E, Foucar K, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deox-ycoformycin and prediction of early relapse. Clin Cancer Res 1999;5: 1665-70. (Pubitemid 29334443)
21. Sausville JE, Salloum R, Sorbara L, Kingma DW, Raffeld M, Kreitman RJ, et al. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 2003;119:213-7. (Pubitemid 37047876)
22. Ramasamy I, Brisco M, Morley A. Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell neoplasms. J Clin Pathol 1992;45:770-5.
23. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17:2257-317. (Pubitemid 38072572)
24. Arons E, Roth L, Sapolsky J, Suntum T, Stetler-Stevenson M, Kreitman RJ. Evidence of Canonical Somatic Hypermutation in Hairy Cell Leukemia. Blood 2011;117:4844-51.
25. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immuno-toxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012;30:1822-8.
26. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102: 810-3. (Pubitemid 36917768)
27. Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev 2011;37:3-10.
28. Matutes E, Oscier D, Montalban C, Berger F, Callet Bauchu E, Dogan A, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008;22: 487-95. (Pubitemid 351386718)
29. Shao H, Calvo KR, Gronborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, et al. Distinguishing Hairy Cell Leukemia Variant from Hairy Cell Leukemia: Development and Validation of Diagnostic Criteria. Leuk Res 2012;37:401-9.
30. DelGiudice I, Matutes E, Morilla R, Morilla A, Owusu Ankomah K, Rafiq F, et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica 2004;89:303-8. (Pubitemid 38788414)
31. Iannitto E, Tripodo C. How I diagnose and treat splenic lymphomas. Blood 2011;117:2585-95.
32. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364:2305-15.
33. Matsushita K, Margulies I, Onda M, Nagata S, Stetler-Stevenson M, Kreitman RJ. Soluble CD22 as aTumor Marker for Hairy Cell Leukemia. Blood 2008;112:2272-7.
34. Robak T, Blasinska-Morawiec M, Krykowski E, Hansz J, Komar-nicki M, Kazimierczak M, et al. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma 1996;22: 107-11. (Pubitemid 26177726)
35. Bastie JN, Cazals Hatem D, Daniel MT, D'Agay MF, Rabian CL, Glaisner S, et al. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: Evaluation of minimal residual disease and CD4+lymphocytopenia after treatment. Leuk Lymphoma 1999;35:555-65. (Pubitemid 30015655)
36. Wheaton S, Tallman MS, Hakimian D, Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996;87: 1556-60. (Pubitemid 26056921)
37. Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, Baur A, Kurrer M, Von Rohr A, et al. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med 2006;130: 374-7.
38. Forconi F, Toraldo F, Sozzi E, Amato T, Raspadori D, Lauria F. Complete molecular remission induced by concomitant cladribine-rituximab treatment in a case of multi-resistant hairy cell leukemia. Leuk Lymphoma 2007;48:2441-3. (Pubitemid 350253477)
39. Narat S, Gandla J, Dogan A, Mehta A. Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma 2005;46:1229-32. (Pubitemid 41087031)
40. Imamura T, Ohtsuka E, Ogata M, Oka F, Kashima K, Kikuchi H, et al. Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant. Int J Hematol 2004;80:432-4. (Pubitemid 40053625)
41. Quach H, Januszewicz H, Westerman D. Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. Haematologica 2005;90 Suppl:ECR26.
42. Sun T, Dittmar K, Koduru P, Susin M, Teichberg S, Brody J. Relationship between hairy cell leukemia variant and splenic lymphoma with villous lymphocytes: presentation of a new concept. Am J Hematol 1996;51:282-8. (Pubitemid 26116368)
43. Ya-In C, Brandwein J, Pantalony D, Chang H. Hairy cell leukemia variant with features of intrasinusoidal bone marrow involvement. Arch Pathol Lab Med 2005;129:395-8. (Pubitemid 40343998)
44. Hockley SL, Else M, Morilla A, Wotherspoon A, Dearden C, Catovsky D, et al. The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma. Br J Haematol 2012;158:347-54.
45. Traverse-Glehen A, Baseggio L, Bauchu EC, Morel D, Gazzo S, Ffrench M, et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood 2008;111:2253-60. (Pubitemid 351454029)
46. Kost CB, Holden JT, Mann KP. Marginal zone B-cell lymphoma: A retrospective immunophenotypic analysis. Cytometry Part B Clin Cytom 2008;74B:282-6.
47. Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 2009;114:4696-702.